<DOC>
	<DOCNO>NCT01381185</DOCNO>
	<brief_summary>The purpose study compare 3 point-of-care method monitor antiplatelet therapy golden standard ( Light transmittance aggregometry-LTA ) high risk population acute myocardial infarction patient . If two method ( PFA-100 , VerifyNOW , Multiplate LTA ) indicate insufficient antiplatelet blockade/high residual reactivity aspirin , clopidogrel , dose aspirin increase 200mg qd dose clopidogrel increase 2x75mg qd.In addition genotyping CYP2C19 ( 6 allele ) perform .</brief_summary>
	<brief_title>REsistance Aspirin Clopidogrel acuTe Myocardial Infarction</brief_title>
	<detailed_description>Dual antiplatelet therapy cornerstone treatment coronary heart disease coronary stent implantation . The interindividual response therapy uniform , however . There subgroups patient , anticipated antiplatelet effect either aspirin , clopidogrel reach . The term aspirin/clopidogrel resistance introduce year ago , recently substitute suitable term - high on-treatment residual platelet reactivity ( HPR ) . Although many assay monitor antiplatelet therapy , uncertainty still remain correlation HPR ischemic vascular event ( in-stent thrombosis , myocardial infarction , etc. ) . Thus platelet aggregation test consider promising method indicate inappropriate/low response aspirin/clopidogrel , however best suit method establish yet . Up-to date light transmittance aggregometry widely accept golden standard , nonetheless labour intensive difficult standardize . On hand many point-of-care aggregation test method like PFA-100 , VerifyNOW , Multiplate etc . introduce , role clinical practice uncertain , however . The big challenge today determine platelet function assay , could reliably indicate future ischemic vascular event ; moreover could potentially use tailor antiplatelet therapy precede event . It demonstrate , gene polymorphism - CYP2C19*2 CYP2C9*3 loss function conjugate increased occurrence stent thrombosis . Within project also plan examine 4 allele examine detail .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>acute myocardial infarction ( verified troponin I elevation STsegment deviation ≥0.1mV ≥2 contiguous ECG lead persist least 20 minute angiographical proof coronary stenosis ) precede antiplatelet medication aspirin100mg qd/5 day PCI pretreatment 600mg Clopidogrel load dose preferably patient drug elute stent implantation sign informed consent stable/unstable angina pectoris active malignancy contraindication antiplatelet therapy increase risk bleeding ( trauma , surgery nonischemic stroke last month ) effective anticoagulation therapy : LMWH , Pradaxa , Xarelto , Warfarin know thrombophile disorder SIRS renal insufficiency ( eGFR 15ml/min ) severe anemia ( &lt; 80 g/l ) polyglobulia ( &gt; 160 g/l ) pregnancy Hematocrit &lt; 0.25 &gt; 0.55</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>myocardial infarction</keyword>
	<keyword>percutaneous coronary intervention ( PCI )</keyword>
	<keyword>high platelet reactivity ( HPR )</keyword>
</DOC>